NCT00642057

Brief Summary

Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 28, 2007

Completed
3 months until next milestone

First Posted

Study publicly available on registry

March 24, 2008

Completed
Last Updated

March 24, 2023

Status Verified

March 1, 2023

First QC Date

December 28, 2007

Last Update Submit

March 22, 2023

Conditions

Keywords

choreadyskinesiahyperkinetic

Interventions

25 mg titrated to optimal dose per patient

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects evaluated here at Baylor in the PDCMDC demonstrating need for tetrabenazine treatment.
  • Willing to sign informed consent.
  • Willing to comply with procedures required as part of this study.

You may not qualify if:

  • Those subjects unwilling to comply with study requirements.
  • Subjects unable to give informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

MeSH Terms

Conditions

ChoreaDyskinesias

Interventions

Tetrabenazine

Condition Hierarchy (Ancestors)

Movement DisordersCentral Nervous System DiseasesNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

QuinolizinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
expanded access
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor, Neurology-PDCMDC

Study Record Dates

First Submitted

December 28, 2007

First Posted

March 24, 2008

Last Updated

March 24, 2023

Record last verified: 2023-03